Search

Displaying results 4761 - 4770 of 5504 in total
  1. Drug

    VX-702

    go.drugbank.com/drugs/DB05470
    Investigational

    It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.

  2. Drug

    FB-825

    go.drugbank.com/drugs/DB17598
    Investigational

    It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).[A258448,L45743]

    Synonyms: Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE)
  3. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]

  4. Drug

    Human ciliary neurotrophic factor, recombinant (E. coli)

    go.drugbank.com/drugs/DB17959
    Experimental

    The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia

    Synonyms: Human ciliary neurotrophic factor, recombinant (E. coli)
  5. Drug

    Dimethylthiambutene

    go.drugbank.com/drugs/DB01444
    ExperimentalIllicit

    It is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available.

  6. Drug

    UDP-alpha-D-glucuronic acid

    go.drugbank.com/drugs/DB03041
    Experimental

    It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.

  7. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  8. Drug

    ATG002

    go.drugbank.com/drugs/DB05068
    Investigational

    ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors,...

  9. Drug

    ATG003

    go.drugbank.com/drugs/DB05069
    Investigational

    ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

  10. Drug

    STI-1499

    go.drugbank.com/drugs/DB16487
    Investigational

    STI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.